As birth rates increase across both developed and developing countries, coupled with the rising incidence of paediatric ...

Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Masimo MASI2.83%increase; green up pointing triangle said Joe Kiani, who previously informed the board of his decision to resign as chief executive, has been terminated by the company. Kiani’s ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

Lastly, Masimo is engaged in ongoing trade secrets litigation against Apple, with a bench trial set to start soon ... 93.76 and a Price / Book ratio of 5.51. This suggests that investors have ...

The modular, scalable monitoring platform offers a range of physiological measurements, including Masimo SET ® pulse oximetry, measure-on-inflation noninvasive blood pressure, continuous ...

Masimo (NASDAQ: MASI) today announced that Vanderbilt University Medical Center (VUMC), a renowned healthcare facility in Nashville, Tennessee, is piloting the use of the Masimo Radius VSM ...

Apple convinced a federal jury on Friday that early versions of health monitoring tech company Masimo's smartwatches ... which is worth about $3.5 trillion, just $250 in damages - the statutory ...

The lawsuit resulted in five of Masimo’s claims being rejected, and a jury being unable to reach agreement on the rest. That will see a new trial held, at a date yet to be set. Masimo got its ...

Apple is off to celebrate, after successfully persuading a federal jury that earlier models of Masimo’s smartwatches had infringed on two of its design patents. The jury sided with Apple, determining ...